Oppenheimer raised the firm’s price target on Tarsus Pharmaceuticals to $59 from $55 and keeps an Outperform rating on the shares. The firm notes Tarsus Pharmaceuticals reported Q4 with a significant topline beat of $13.1M vs. its anticipated $5.8M and the Street’s $5.5M due to greater than anticipated bottles shipped as well as significantly better than expected G/N. Oppenheimer highlights however that the G/N performance is mostly driven by an increase in noncontracted coverage.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TARS:
- Tarsus Pharmaceuticals reports Q4 EPS ($1.31), consensus ($1.36)
- Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Achievements
- Is TARS a Buy, Before Earnings?
- Tarsus Pharmaceuticals announces results from Carpo, phase 2a trial of TP-05
- Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024
